

**BEYER WEAVER & THOMAS, LLP**

INTELLECTUAL PROPERTY LAW  
500 12th Street, Suite 200, Oakland, CA 94607  
Telephone: (510) 663-1100 Facsimile: (510) 663-0920  
www.beyerlaw.com

RECEIVED  
CENTRAL FAX CENTER

AUG 02 2006

**FACSIMILE COVER SHEET**

August 2, 2006

**Receiver:** Srivastava, Kailash, C./Art Unit: 1655  
USPTO

**FAX # :** (571) 273-8300

**Sender:** Leslie Russell, Patent Secretary for:  
Jeffrey K. Weaver, Registration No. 31,314

**Your Ref. No.:** 10/719,988

**Our Ref. No.:** CYTOP135X1

**Re:** Response to Restriction Requirement

**Pages Including Cover Sheet(s):** 3

**Fax Contents:**

Fax Cover Sheet - 1 Page  
Response to Restriction Requirement - 2 Pages

**MESSAGE:**

---

**CONFIDENTIALITY NOTE**

The information contained in this facsimile (FAX) message is legally privileged and confidential information intended only for the use of the receiver or firm named above. If the reader of this message is not the intended receiver, you are hereby notified that any dissemination, distribution or copying of this FAX is strictly prohibited. If you have received this FAX in error, please immediately notify the sender at the telephone number provided above and return the original message to the sender at the address above via the United States Postal Service. Thank you.

---

AUG. 2. 2006 12:14PM

5106630920

RECEIVED  
CENTRAL FAX CENTER

NO. 096

P. 2

AUG 12 2006

---

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

---

In re application of: Mattheakis et al.

Attorney Docket No.: CYTOP135X1

Application No.: 10/719,988

Examiner: Srivastava, Kailash, C.

Filed: November 20, 2003

Group: 1655

Title: PREDICTING HEPATOTOXICITY USING  
CELL BASED ASSAYS

---

**CERTIFICATE OF TRANSMISSION**

I hereby certify that this correspondence is being transmitted via facsimile to the U.S. Patent and Trademark Office, Attention Examiner Srivastava, Kailash, C. at facsimile telephone number (571) 273-7500 on August 2, 2006.

Signed: 

Leslie Russell

**RESPONSE TO RESTRICTION REQUIREMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450


Dear Sir:

In response to the Restriction Requirement dated July 3, 2006, Applicants hereby elect, with traverse, Group I, claims 1-7 and 10-11 to prosecute in the above-identified patent application.

Applicants respectfully traverse the Restriction Requirement because it is believed that claims of Group II (claims 8 and 9) can be examined with little additional effort. Claims 8 and 9 depend from generic claim 1 and therefore include all features of claim 1. They additionally recite the use of "transformed or immortalized cells," which refers to the hepatocytes recited in claim 1. If the transformed/immortalized hepatocytes of claims 8 and 9 require searching in specific classes/subclasses, then any relevant prior art located in such search area should include a relation to the features recited in claim 1. This suggests that a search for the claims of Group I should subsume the class/subclass identified for Group II as well. It is respectfully requested that the claims of Groups I and II be joined and examined together.

If any fees are due in connection with the filing this Response to Restriction Requirement, the Commissioner is hereby authorized to charge such fees to Deposit Account 500388 (Order No. CYTOP135X1).

Respectfully submitted,  
BEXER WEAVER & THOMAS, LLP

  
Jeffrey K. Weaver  
Registration No. 31,314

P.O. Box 70250  
Oakland, CA 94612-0250